

Prevalence of Residual Symptoms in Subjects with Bipolar Disorder at a Tertiary Care Hospital

Parag Dhoble

Associate Professor, Department of Psychiatry, RD Gardi Medical College, Ujjain, Madhya Pradesh, India.

ABSTRACT

Background: Bipolar, or manic-depressive, disorders are frequent, severe, and often chronic mental illnesses. They are associated with considerable morbidity and mortality, and for many patients, an initial episode of mania or depression evolves into a life-long illness. The present study was conducted to assess prevalence of residual symptoms in subjects with bipolar disorder.

Materials and Methods: This cross-sectional study was carried out to assess prevalence of residual symptoms in 300 subjects with bipolar disorder. Remission was defined cross-sectionally as scores of ≤ 7 on the HAM-D-17 and ≤ 7 on the YMRS. Information was obtained from patient, relatives, and review of treatment records. The patients were evaluated clinically during assessment. The recorded data was compiled, and data analysis was done using SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA). The obtained data were analyzed using descriptive statistics, such as frequency, percentage, mean, and standard deviation (SD). P-value less than 0.05 was considered statistically significant.

Results: A total of 300 patients with BD currently in remission according to the selection criteria formed the study sample. In 51 subjects there were no residual symptoms. HDRS scale gives prevalence of residual depressive symptoms. The most common residual depressive symptoms in the entire sample according to the HAM-D was impairment in insight, psychic

anxiety, loss of interest in work/activities and somatic psychic. The prevalence of residual manic symptoms as per the YMRS shows that the most common residual manic symptom was poor insight, followed by sleep disturbance and irritation.

Conclusion: The study concluded that the most common residual depressive symptoms was impairment in insight, psychic anxiety, loss of interest in work/activities and somatic psychic. The most common residual manic symptom was poor insight, followed by sleep disturbance and irritation.

Keywords: HDRS, Residual Depressive Symptoms, YMRS, Residual Manic Symptom.


*Correspondence to:

Dr. Parag Dhoble,
Associate Professor,
Department of Psychiatry,
RD Gardi Medical College,
Ujjain, Madhya Pradesh, India.

Article History:

Received: 29-07-2019, Revised: 22-08-2019, Accepted: 13-09-2019

Access this article online

Website: www.ijmrp.com	Quick Response code 
DOI: 10.21276/ijmrp.2019.5.5.065	

INTRODUCTION

Bipolar disorder (BD) is a serious, commonly disabling psychiatric condition that is tragically, on occasion, fatal. It is characterized by recurrent episodes of depression and mood elevation (mania or hypomania). Bipolar spectrum illness (comprising BD in its broadest sense), including bipolar I disorder (BDI, requiring a lifetime history of at least one manic episode), bipolar II disorder (BDII, requiring a lifetime history of major depressive and hypomanic episodes, without any history of mania), and BD not otherwise specified (BDNOS, including subthreshold bipolar presentations), may affect as much as 4.4% of the US population.¹ Despite the availability of several treatment strategies, the longitudinal course of BD is characterized by low recovery rate, high recurrence rate, poor interepisodic functioning, and high prevalence of physical- and substance use-related comorbidities.^{2,3} Residual subsyndromal depressive symptoms following recovery from a unipolar major depressive episode

(MDE) are associated with a significantly faster recurrence compared with a fully symptom-free recovery (asymptomatic recovery).^{4,5} Persisting subsyndromal symptoms of BD (SSBD) impact on patients functionality and quality of life (QoL), and put them on elevated risk of relapse.⁶ Several studies have demonstrated that a significant proportion of patients with BD continue to have residual or subsyndromal symptoms during the interepisodic phase.^{7,8} Residual or subsyndromal symptoms in BD have been shown to be strongly associated with social, occupational, and cognitive impairment.⁹⁻¹¹ Residual depressive symptoms have an adverse impact on overall functioning, whereas residual manic symptoms have a negative impact on financial issues, family stigma, interpersonal relationships, sexual functioning, and occupational stigma.⁸ The present study was conducted to assess prevalence of residual symptoms in subjects with bipolar disorder.

MATERIALS AND METHODS

This cross-sectional study was carried out to assess prevalence of residual symptoms in 300 subjects with bipolar disorder. Before the commencement of the study ethical approval was taken from the Ethical Committee of the institute and written consent was taken from the patient after explaining the study. Patients included in the study were the participants who fulfil the diagnosis of BD as per the DSM-IV criteria¹² assessed using the Mini International Neuropsychiatric Interview-Extended Version (MINI-PLUS 6.0 version).¹³ Participants were required to be aged 18 years or more, having illness duration of at least 2 years, and minimum of two lifetime episodes (BD-I or BD-II). They had to be in remission for a minimum of 3 months before induction. Remission was defined cross-sectionally as scores of ≤ 7 on the HAM-D-17¹⁴ and ≤ 7 on the YMRS.¹⁵ In addition, participants had to be “clinically

stable” for the past 3 months, defined as no change in medications or dosages of medications in the past 3 months. Patients with medical or substance-induced BD, those with intellectual disability, and those not willing to participate in the study were excluded from the study. Information was obtained from patient, relatives, and review of treatment records. The patients were evaluated clinically during assessment. The recorded data was compiled, and data analysis was done using SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA). The obtained data were analyzed using descriptive statistics, such as frequency, percentage, mean, and standard deviation (SD). Parametric statistics such as ANOVA and Student’s t-test and nonparametric statistics such as Chi-square test and Mann–Whitney-U-test were used for comparison. P-value less than 0.05 was considered statistically significant.

Table 1: Prevalence of residual depressive and manic symptoms

HDRS scale - residual depressive symptoms	Frequency (n=249),
Depressed mood	27
Feelings of guilt	12
Suicide	15
Insomnia - early	45
Insomnia – middle	26
Insomnia – late	29
Work/activities	78
Retardation	5
Agitation	34
Anxiety-psychic	81
Anxiety-somatic	56
Somatic symptoms - gastrointestinal	23
Somatic symptoms – general	19
Genital symptoms	8
Hypochondriasis	5
Weight loss	9
Insight	87
YMRS - residual manic symptoms	Frequency in the entire sample (n=249)
Elevated mood	34
Increased motor activity/energy	16
Sexual interest	5
Sleep	97
Irritability	48
Speech (rate/amount)	45
Language-thought disorder	44
Content	3
Disruptive/aggressive behaviour	7
Appearance	45
Insight	98

RESULTS

A total of 300 patients with BD currently in remission according to the selection criteria formed the study sample. In 51 subjects there were no residual symptoms. HDRS scale gives prevalence of residual depressive symptoms. The most common residual depressive symptoms in the entire sample according to the HAM-D was impairment in insight, psychic anxiety, loss of interest in work/activities and somatic psychic. The prevalence of residual manic symptoms as per the YMRS shows that the most common residual manic symptom was poor insight, followed by sleep disturbance and irritation.

DISCUSSION

Neurotransmitter systems probably involved in the pathophysiology of bipolar illnesses include serotonergic pathways, as well as the hypothalamic–pituitary–thyroid and –adrenal systems.¹⁶⁻¹⁹ Family studies have consistently demonstrated the genetic liability of bipolar disorders. First-degree relatives of affected individuals have a 10-fold increased risk for developing the disease compared to relatives of unaffected controls.²⁰ A total of 300 patients with BD currently in remission according to the selection criteria formed the study sample. In 51 subjects there

were no residual symptoms. HDRS scale gives prevalence of residual depressive symptoms. The most common residual depressive symptoms in the entire sample according to the HAM-D was impairment in insight, psychic anxiety, loss of interest in work/activities and somatic psychic. The prevalence of residual manic symptoms as per the YMRS shows that the most common residual manic symptom was poor insight, followed by sleep disturbance and irritation. The reported prevalence of residual symptoms, the reported prevalence in the existing literature is in the range of 14%–70%.²¹⁻²⁴

Data from STEP-BD trial which evaluated residual symptoms on MADRS reported sadness, lassitude, inability to feel, and pessimistic thoughts,²⁵ whereas other studies have reported depressed mood, somatic anxiety, impact on work and activities, psychic anxiety, and gastrointestinal and somatic symptoms to be the common residual symptoms.²⁶

Sleep disturbances were one of the most common manic residual symptoms in the previous literature.²⁷⁻²⁹ Keller et al found that low serum lithium levels in 94 bipolar individuals were significantly associated with the presence of subsyndromal affective symptoms and a higher risk for major affective episode recurrence.³⁰

CONCLUSION

The study concluded that the most common residual depressive symptoms was impairment in insight, psychic anxiety, loss of interest in work/activities and somatic psychic. The most common residual manic symptom was poor insight, followed by sleep disturbance and irritation.

REFERENCES

1. Merikangas, K.R., Akiskal, H.S., Angst, J., Greenberg, P.E., Hirschfeld, R.M., Petukhova, M., Kessler, R.C. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. *Arch. Gen. Psychiatry* 2007; 64 (5), 543–52.
2. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. *Am J Psychiatry* 1995;152:1635-40.
3. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, et al. Psychosocial disability in the course of bipolar I and II disorders: A prospective, comparative, longitudinal study. *Arch Gen Psychiatry* 2005;62:1322-30.
4. Judd LL, Paulus MP, Zeller P. The role of residual subthreshold depressive symptoms in early episode relapse in unipolar major depressive disorder. *Arch Gen Psychiatry*. 1999;56(8):764-5.
5. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, Mueller T, Solomon DA, Keller MB. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? *Am J Psychiatry*. 2000;157(9):1501-4.
6. Marangell LB. The importance of subsyndromal symptoms in bipolar disorder. *J Clin Psychiatry* (2004) 65 Suppl 10:24–7.
7. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. *Arch Gen Psychiatry* 2003;60:261-9.
8. Samalin L, de Chazeron I, Vieta E, Bellivier F, Llorca PM. Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. *Bipolar Disord* 2016;18:164-73.

9. Altshuler LL, Post RM, Black DO, Keck PE Jr., Nolen WA, Frye MA, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: Results of a large, multisite study. *J Clin Psychiatry* 2006; 67: 1551-60.
10. Marangell LB. The importance of subsyndromal symptoms in bipolar disorder. *J Clin Psychiatry* 2004;65 Suppl 10:24 7.
11. Samalin L, Boyer L, Murru A, Pacchiarotti I, Reinares M, Bonnin CM, et al. Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder. *J Affect Disord* 2017;210:280 6.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC, USA: American Psychiatric Association; 1994.
13. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM IV and ICD 10. *J Clin Psychiatry* 1998;59 Suppl 20:22-33.
14. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;23:56-62.
15. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. *Br J Psychiatry* 1978;133:429-35.
16. Sobczak S, Honig A, van Duinen MA, et al. Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. *Bipolar Disord* 2002;4:347–56.
17. Shiah IS, Yatham LN. Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. *Bipolar Disord* 2000;2:77–92.
18. Bauer M, London ED, Silverman DH, et al. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. *Pharmacopsychiatry* 2003;36(suppl 3):S215–21.
19. Rybakowski JK, Twardowska K. The dexamethasone/corticotropin releasing hormone test in depression in bipolar and unipolar affective illness. *J Psychiatry Res* 1999;33:363–70.
20. Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. *Am J Med Genet* 2003;123C:48–58.
21. Marangell LB. The importance of subsyndromal symptoms in bipolar disorder. *J Clin Psychiatry* 2004;65 Suppl 10:24 7.
22. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, et al. Predictors of recurrence in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP BD). *Am J Psychiatry* 2006;163:217-24.
23. Samalin L, Reinares M, de Chazeron I, Torrent C, Bonnin CM, Hidalgo Mazzei D, et al. Course of residual symptoms according to the duration of euthymia in remitted bipolar patients. *Acta Psychiatr Scand* 2016;134:57-64.
24. Bonnin CM, Martínez Arán A, Torrent C, Pacchiarotti I, Rosa AR, Franco C, et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: A long term, follow up study. *J Affect Disord* 2010;121:156-60.
25. Keller MB, Lavori PW, Kane JM, Gelenberg AJ, Rosenbaum JF, Walzer EA, Baker LA. Subsyndromal symptoms in bipolar disorder: a comparison of standard and low serum levels of lithium. *Arch Gen Psychiatry*. 1992;49(5):371-376

26. Marangell LB, Dennehy EB, Miyahara S, Wisniewski SR, Bauer MS, Rapaport MH, et al. The functional impact of subsyndromal depressive symptoms in bipolar disorder: Data from STEP BD. *J Affect Disord* 2009;114:58-67.
27. Vieta E, Sánchez Moreno J, Lahuerta J, Zaragoza S; EDHIPO Group (Hypomania Detection Study Group). Subsyndromal depressive symptoms in patients with bipolar and unipolar disorder during clinical remission. *J Affect Disord* 2008;107:169-74.
28. Gruber J, Harvey AG, Wang PW, Brooks JO 3rd, Thase ME, Sachs GS, et al. Sleep functioning in relation to mood, function, and quality of life at entry to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP BD). *J Affect Disord* 2009;114:41-9.
29. Ram D, Ram D. Subsyndromal states in bipolar disorder. *Indian J Psychiatry* 2010;52:367-70.
30. Sylvia LG, Dupuy JM, Ostacher MJ, Cowperthwait CM, Hay AC, Sachs GS, et al. Sleep disturbance in euthymic bipolar patients. *J Psychopharmacol* 2012;26:1108-12.

Source of Support: Nil.

Conflict of Interest: None Declared.

Copyright: © the author(s) and publisher. IJMRP is an official publication of Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article as: Parag Dhoble. Prevalence of Residual Symptoms in Subjects with Bipolar Disorder at a Tertiary Care Hospital. *Int J Med Res Prof.* 2019 Sept; 5(5): 286-89.
DOI:10.21276/ijmrp.2019.5.5.065